21 U.S.C. § 360n–1

(a) In general If the Secretary designates a drug under section 355f(d) of this title as a qualified infectious disease product, then the Secretary shall give priority review to the first application submitted for approval for such drug under section 355(b) of this title , or section 262(a) of title 42 , that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness. (b) Construction Nothing in this section shall prohibit the Secretary from giving priority review to a human drug application or efficacy supplement submitted for approval under section 355(b) of this title that otherwise meets the criteria for the Secretary to grant priority review.